Stock ZVRA ZEVRA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Zevra Therapeutics, Inc.

Equities

ZVRA

US4884452065

Market Closed - Nasdaq
Other stock markets
 21:00:00 28/06/2024 BST 		5-day change 1st Jan Change
4.9 USD +1.87% Intraday chart for Zevra Therapeutics, Inc. +12.39% -25.19%
06-25 Zevra Therapeutics, Inc. Expands Executive Leadership Team CI
06-04 Zevra Therapeutics Files $350 Million Mixed-Shelf; Shares Fall After Hours MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Zevra Therapeutics Expands Executive Leadership Team
AQ
Zevra Therapeutics, Inc. Expands Executive Leadership Team
CI
Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders
PR
Zevra Therapeutics Files $350 Million Mixed-Shelf; Shares Fall After Hours
MT
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting
AQ
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of Kp1077 for Idiopathic Hypersomnia At Sleep 2024 Annual Meeting
CI
Transcript : Zevra Therapeutics, Inc. - Shareholder/Analyst Call
Zevra Therapeutics to Participate at Upcoming Investor Events
AQ
Earnings Flash (ZVRA) ZEVRA THERAPEUTICS Reports Q1 Revenue $3.4M
MT
Transcript : Zevra Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024
Zevra Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Zevra Therapeutics: Q1 Earnings Snapshot
AQ
Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
PR
Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024
AQ
Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024
AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
PR
Zevra Therapeutics Metabolic Disorder Treatment Shows 'Meaningful Slowing of Disease Progression'
MT
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ZVRA Stock
  4. News Zevra Therapeutics, Inc.